O.C. BUSINESS PLUS : ORANGE COUNTY BRIEFLY : FDA Approves Interpore Cross’ BonePlast
Interpore Cross International said Wednesday that it received clearance from the Food and Drug Administration to market its new BonePlast product, a biocompatible, plaster-of-Paris-based material that is replaced with bone during healing.
The Irvine medical device company said the FDA approved the use of BonePlast in bony voids or gaps of the skeletal system, such as the extremities, spine and pelvis.
The company plans to begin selling the product in the U.S. in the fourth quarter.
Interpore’s stock moved up about 10%, or 75 cents a share, to $7.81.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
